Danaher Co. (NYSE:DHR) Position Increased by Aprio Wealth Management LLC

Aprio Wealth Management LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 37.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,787 shares of the conglomerate’s stock after buying an additional 486 shares during the period. Aprio Wealth Management LLC’s holdings in Danaher were worth $497,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. XML Financial LLC boosted its stake in Danaher by 3.6% in the 4th quarter. XML Financial LLC now owns 5,382 shares of the conglomerate’s stock worth $1,245,000 after purchasing an additional 186 shares during the period. Regal Investment Advisors LLC boosted its stake in Danaher by 78.7% in the 4th quarter. Regal Investment Advisors LLC now owns 8,283 shares of the conglomerate’s stock worth $1,916,000 after purchasing an additional 3,647 shares during the period. Lighthouse Investment Partners LLC acquired a new position in Danaher in the 4th quarter worth approximately $624,000. Mmbg Investment Advisors CO. boosted its stake in Danaher by 22.2% in the 4th quarter. Mmbg Investment Advisors CO. now owns 15,155 shares of the conglomerate’s stock worth $3,506,000 after purchasing an additional 2,750 shares during the period. Finally, Greystone Financial Group LLC acquired a new position in Danaher in the 4th quarter worth approximately $5,864,000. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research analyst reports. The Goldman Sachs Group increased their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners increased their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen increased their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Danaher Stock Performance

NYSE DHR opened at $268.79 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market capitalization of $199.09 billion, a price-to-earnings ratio of 45.56, a P/E/G ratio of 4.55 and a beta of 0.83. The company’s fifty day moving average is $271.07 and its two-hundred day moving average is $258.64. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business earned $2.05 EPS. The firm’s revenue was down 2.9% on a year-over-year basis. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.